Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25748
Title: Relationship between amyloid and tau levels and its impact on tau spreading.
Austin Authors: Doré, Vincent ;Krishnadas, Natasha ;Bourgeat, Pierrick;Huang, Kun ;Li, Shenpeng;Burnham, Samantha;Masters, Colin L ;Fripp, Jurgen;Villemagne, Victor L ;Rowe, Christopher C 
Affiliation: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
The Australian Dementia Network (ADNeT), Melbourne, Australia
Health and Biosecurity Flagship, The Australian eHealth Research Centre, Brisbane, Queensland, Australia
Health and Biosecurity Flagship, The Australian eHealth Research Centre, Melbourne, Victoria, Australia
Molecular Imaging and Therapy
Issue Date: Jul-2021
Date: 2021-01-26
Publication information: European Journal of Nuclear Medicine and Molecular Imaging 2021; 48(7): 2225-2232
Abstract: Previous studies have shown that Aβ-amyloid (Aβ) likely promotes tau to spread beyond the medial temporal lobe. However, the Aβ levels necessary for tau to spread in the neocortex is still unclear. Four hundred sixty-six participants underwent tau imaging with [18F]MK6420 and Aβ imaging with [18F]NAV4694. Aβ scans were quantified on the Centiloid (CL) scale with a cut-off of 25 CL for abnormal levels of Aβ (A+). Tau scans were quantified in three regions of interest (ROI) (mesial temporal (Me); temporoparietal neocortex (Te); and rest of neocortex (R)) and four mesial temporal region (entorhinal cortex, amygdala, hippocampus, and parahippocampus). Regional tau thresholds were established as the 95%ile of the cognitively unimpaired A- subjects. The prevalence of abnormal tau levels (T+) along the Centiloid continuum was determined. The plots of prevalence of T+ show earlier and greater increase along the Centiloid continuum in the medial temporal area compared to neocortex. Prevalence of T+ was low but associated with Aβ level between 10 and 40 CL reaching 23% in Me, 15% in Te, and 11% in R. Between 40 and 70 CL, the prevalence of T+ subjects per CL increased fourfold faster and at 70 CL was 64% in Me, 51% in Te, and 37% in R. In cognitively unimpaired, there were no T+ in R below 50 CL. The highest prevalence of T+ were found in the entorhinal cortex, reaching 40% at 40 CL and 80% at 60 CL. Outside the entorhinal cortex, abnormal levels of cortical tau on PET are rarely found with Aβ below 40 CL. Above 40 CL prevalence of T+ accelerates in all areas. Moderate Aβ levels are required before abnormal neocortical tau becomes detectable.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25748
DOI: 10.1007/s00259-021-05191-9
ORCID: 0000-0002-8051-0558
Journal: European Journal of Nuclear Medicine and Molecular Imaging
PubMed URL: 33495928
Type: Journal Article
Subjects: Alzheimer’s disease
Aβ-amyloid imaging
Neurodegeneration
Positron emission tomography
Tau imaging
Tauopathies
Appears in Collections:Journal articles

Show full item record

Page view(s)

74
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.